References
- CarlssonAA paradigm shift in brain researchScience20092941021102411691978
- JankovicJPoeweWTherapies in Parkinson’s diseaseCurr Opin Neurol20122543344722691758
- SingerCManaging the patient with newly diagnosed Parkinson diseaseCleve Clin J Med201279Suppl 2S3S722761267
- StocchiFThe therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson’s diseaseParkinsonism Relat Disord200915Suppl 3S68S7120083012
- MüllerTPharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complicationsClin Neuropharmacol201336849123673910
- ReichmannHEmreMOptimizing levodopa therapy to treat wearing-off symptoms in Parkinson’ disease: focus on levodopa/carbidopa/entacaponeExpert Rev Neurother20121211913122288667
- ReichmannHBoasJMacmahonDEfficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuationsActa Neurol Scand2005111212815595934
- NyholmDEhrneboMLewanderTFrequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteersActa Neurol Scand2013127212413222762460
- NyholmDLewanderTGomes-TrolinCPharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteersClin Neuropharmacol20123511111722549097
- FargelMGrobeBOesterleEHastedtCRuppMTreatment of Parkinson’s disease: a survey of patients and neurologistsClin Drug Investig200727207218
- NausiedaPAPfeifferRFTagliatiMKastenholzKVDeRocheCSlevinJTA multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson’s diseaseClin Therap200527586315763606
- PerssonUSvenssonJPetterssonBA new reimbursement system for innovative pharmaceuticals combining value-based and free market pricingAppl Health Econ Health Policy201210421722522676213
- BatemanICarsonRDayBEconomic Valuation with Stated Preference Techniques: a manualCheltenhamEdward Elgar2002
- LökkJBorgSSvenssonJPerssonULjunggrenGDrug and treatment costs in Parkinson’s disease patients in SwedenActa Neurol Scand201212514214721470194
- CarlssonPTinghögGLäkemedel – När är det rimligt att betala själv? [Swedish: Drugs –when is it reasonable to pay yourself?]StockholmSNS Publishing2013
- BlumenscheinKBlomquistGJohannessonMHornNFreemanPEliciting willingness to pay without bias: evidence from a field experimentEcon J2008118114137
- WorthPFHow to treat Parkinson’s disease in 2013Clin Med201313939623472504
- PandeySParkinson’s disease: recent advancesJ Assoc Physicians India201260303223409418
- BrotchieJJennerPNew approaches to therapyInt Rev Neurobiol20119812315021907085
- StocchiFUse of apomorphine in Parkinson’s diseaseNeurol Sci200829Suppl 5S383S38619381769
- FernandezHHOdinPLevodopa-carbidopa intestinal gel for treatment of advanced Parkinson’s diseaseCurr Med Res Opin20112790791921351823
- VarmaTRFoxSHEldridgePRDeep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson’s disease patients previously reliant on apomorphineJ Neurol Neurosurg Psychiatry20037417017412531942
- SprengerFSSeppiKPoeweWDrug safety evaluation of rotigotineExpert Opin Drug Saf20121150351222468676